Sfoglia per Autore
Clinical severity instruments
2005-01-01 Zangrilli, A; Talamonti, M; Saraceno, R; Chimenti, S
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics
2007-01-01 Papoutsaki, M; Chimenti, Ms; Costanzo, A; Talamonti, M; Zangrilli, A; Giunta, A; Bianchi, L; Chimenti, S
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience
2007-01-01 Costanzo, A; Peris, K; Talamonti, M; Di Cesare, A; Fargnoli, Mc; Botti, E; Chimenti, S
Long-term efficacy of adalimumab in generalized pustular psoriasis
2008-01-01 Zangrilli, A; Papoutsaki, M; Talamonti, M; Chimenti, S
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study
2008-01-01 Papoutsaki, M; Chimenti, Ms; Talamonti, M; Zangrilli, A; Teoli, M; Kroegler, B; Perricone, R; Chimenti, S
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis
2009-01-01 Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers
2009-01-01 Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy
2009-01-01 Costanzo, A; Talamonti, M; Spallone, G; Botti, E; Chimenti, Ms; Papoutsaki, M; Chimenti, S
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience
2010-01-01 Esposito, M; Giunta, A; Mazzotta, A; Babino, G; Talamonti, M; Chimenti, Ms; Chimenti, S
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab
2010-01-01 Papoutsaki, M; Talamonti, M; Giunta, A; Costanzo, A; Ruzzetti, M; Teoli, M; Chimenti, S
Efalizumab
2011-01-01 Talamonti, M; Spallone, G; Di Stefani, A; Costanzo, A; Chimenti, S
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
2011-01-01 Talamonti, M; Galluzzo, M; Teoli, M; Bavetta, M; Chimenti, S; Costanzo, A
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension
2011-01-01 Talamonti, M; Teoli, M; Botti, E; Spallone, G; Chimenti, S; Costanzo, A
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study
2012-01-01 Teoli, M; Zangrilli, A; Chimenti, Ms; Talamonti, M; Bavetta, M; Graceffa, D; Perricone, R; Chimenti, S
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome
2012-01-01 Talamonti, M; Galluzzo, M; Chiricozzi, A; Teoli, M; Bavetta, M; Costanzo, A; Chimenti, S
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis
2012-09-01 Spallone, G; Botti, E; Talamonti, M; Marinari, B; Pinetti, V; Chimenti, S; Costanzo, A
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis
2012-09-01 Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A
Genetic variations in IL6 and IL12B as protective markers for psoriasis
2013-01-01 Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, Ad; Costanzo, A
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes
2013-01-01 Kemeny, L; Yankova, R; Talamonti, M; Vaclavkova, A; Burcklen, M; Thomas, G; D'Ambrosio, D
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris
2013-01-01 Di Stefani, A; Galluzzo, M; Talamonti, M; Chiricozzi, A; Costanzo, A; Chimenti, S
Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
---|---|---|---|---|
1-gen-2005 | Clinical severity instruments | Zangrilli, A; Talamonti, M; Saraceno, R; Chimenti, S | Contributo in libro | |
1-gen-2007 | Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics | Papoutsaki, M; Chimenti, Ms; Costanzo, A; Talamonti, M; Zangrilli, A; Giunta, A; Bianchi, L; Chimenti, S | Articolo su rivista | |
1-gen-2007 | Long-term treatment of plaque psoriasis with efalizumab: an Italian experience | Costanzo, A; Peris, K; Talamonti, M; Di Cesare, A; Fargnoli, Mc; Botti, E; Chimenti, S | Articolo su rivista | |
1-gen-2008 | Long-term efficacy of adalimumab in generalized pustular psoriasis | Zangrilli, A; Papoutsaki, M; Talamonti, M; Chimenti, S | Articolo su rivista | |
1-gen-2008 | Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study | Papoutsaki, M; Chimenti, Ms; Talamonti, M; Zangrilli, A; Teoli, M; Kroegler, B; Perricone, R; Chimenti, S | Intervento a convegno | |
1-gen-2009 | HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis | Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S | Intervento a convegno | |
1-gen-2009 | Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers | Costanzo, A; Talamonti, M; Botti, E; Spallone, G; Papoutsaki, M; Chimenti, S | Articolo su rivista | |
1-gen-2009 | Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy | Costanzo, A; Talamonti, M; Spallone, G; Botti, E; Chimenti, Ms; Papoutsaki, M; Chimenti, S | Articolo su rivista | |
1-gen-2010 | Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience | Esposito, M; Giunta, A; Mazzotta, A; Babino, G; Talamonti, M; Chimenti, Ms; Chimenti, S | Articolo su rivista | |
1-gen-2010 | The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab | Papoutsaki, M; Talamonti, M; Giunta, A; Costanzo, A; Ruzzetti, M; Teoli, M; Chimenti, S | Articolo su rivista | |
1-gen-2011 | Efalizumab | Talamonti, M; Spallone, G; Di Stefani, A; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-gen-2011 | Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis | Talamonti, M; Galluzzo, M; Teoli, M; Bavetta, M; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-gen-2011 | Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension | Talamonti, M; Teoli, M; Botti, E; Spallone, G; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2012 | Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study | Teoli, M; Zangrilli, A; Chimenti, Ms; Talamonti, M; Bavetta, M; Graceffa, D; Perricone, R; Chimenti, S | Articolo su rivista | |
1-gen-2012 | Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome | Talamonti, M; Galluzzo, M; Chiricozzi, A; Teoli, M; Bavetta, M; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-set-2012 | Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis | Spallone, G; Botti, E; Talamonti, M; Marinari, B; Pinetti, V; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-set-2012 | Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis | Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A | Intervento a convegno | |
1-gen-2013 | Genetic variations in IL6 and IL12B as protective markers for psoriasis | Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, Ad; Costanzo, A | Intervento a convegno | |
1-gen-2013 | A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes | Kemeny, L; Yankova, R; Talamonti, M; Vaclavkova, A; Burcklen, M; Thomas, G; D'Ambrosio, D | Intervento a convegno | |
1-gen-2013 | Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris | Di Stefani, A; Galluzzo, M; Talamonti, M; Chiricozzi, A; Costanzo, A; Chimenti, S | Articolo su rivista |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile